AAR Corp. (NYSE:AIR) Q3 2025 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Denise Pacioni - Director of Investor Relations John Holmes - Chairman, President and Chief Executive Officer Sean Gillen - Senior Vice President and Chief Financial Officer Conference Call Participants Kenneth Herbert - RBC Capital Markets Louie DiPalma - William Blair Michael Leshock - KeyBanc Capital Markets Scott Mikus - Melius Research Joshua Sullivan - The Benchmark Company Michael Ciarmoli - Truist Se ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年3月6日， 高德美（Galderma， SIX:GALD ）发布2024年年度财务报告。高德美 专注于皮肤科领域的 全球龙头企业，业务涵盖注射美容、皮肤护理和治疗性皮肤科产品。 2024年财务表现 业务增长驱动因素 注射美容 ：净销售额22.99亿美元，同比增长9.6%。其中，肉毒吉适（Dysport）和聚左旋乳酸填充剂 塑妍萃 （Sculptra）均实现了两位数增长。 产品和市场表现 净销售额 ：达到44.1亿美元（约320亿人民币），按固定汇率计算同比增长9.3%。 核心EBITDA（息税折旧摊销前利润） ：达到10.31亿美元，首次突破10亿美元大关，核心EBITDA利润 率为23.4%，较2023年提高30个基点。 债务杠杆率 ：截至2024年12月，杠杆率降至2.3倍，并成功发行了首笔瑞士债券。 皮肤护理 ：净销售额13.31亿美元，同比增长10.7%。Cetaphil和Alastin品牌表现强劲，尤其是在国际 市场。 治疗性皮肤科 ...

"七巨头"（简称Mag-7）约占标普500指数总市值的三分之一，一直是近期季度盈利增长的主要贡献者。在 2023年，S&P 500的盈利增长为4.1%，但如果排除Mag-7所带来的盈利增长，增长率则跌至-1.3%。 尽管 Mag-7有望持续增长，但我们预计未来盈利增长将进一步扩展到指数中的其他成分股（即"S&P 493"）。 这 一趋势已经在2024年第四季度初露端倪。 Tajinder Dhillon LSEG理柏管理 基本面研究负责人 具体而言，2024年Mag-7的盈利增长高达33.4%，相比之下，整体S&P 500指数的增长率仅为10.0%。当我 们将Mag-7的盈利增长排除在外，整体指数的增长率则下降至5.2%。 展望2025年，Mag-7的盈利增长预计 为18.6%，依然强劲，而整体指数的增长率预计为14.1%。然而， 若将Mag-7的盈利增长排除在外，整体指 数的增长率也仅下降至13.0%。 换言之，在2024年，Mag-7对S&P 500指数盈利增长的贡献率达到了约 57%。这一贡献率预计将在2025年有所回调，下降至约28%。如果我们将英伟达（Nvidia）排除在外， Mag-7对S&P 5 ...

图片来源： DeepSeek DeepSeek 最近公开其 AI 模型可能的盈利情况——但有一些附加条件。 在 X 上的一篇帖子中， DeepSeek 称 其在线服务的"成本利润率"为 545% 。该利润率是基于"理论收入"计算的。 在一篇更长的 GitHub 帖子结尾详细讨论了这些数字，概述了其实现"更高吞吐量和更低延迟"的方法。DeepSeek 写道，当它查看其 V3 和 R1 模型在 24 小 时内的使用情况时，如果所有使用都按 R1 定价计费， DeepSeek 每天的收入将达到 562,027 美元。 与此同时，租赁所需的 GPU （图形处理单元）的成本仅为 87,072 美元。 DeepSeek 承认，由于多种原因，其实际收入 "显著低于"预期，例如夜间折扣、 V3 的较低定价，以及"只有一部分服务实现了商业化"，而网络和应用程序 的访问仍然是免费的。 当然，如果应用程序和网站不是免费的，并且没有其他折扣，使用量可能会显著降低。因此这更像是对未来潜在利润率的一个预估，而不是 DeepSeek 当前 现实情况。 DeepSeek 在关于人工智能成本和潜在盈利能力的更广泛讨论中分享这些数字。 Deep ...

3月1日中午，DeepSeek在知乎平台发布首条文章，公布模型推理成本利润细节，并披露成本利润率关键信息。DeepSeek称，假定GPU租赁成本为2美元/小时，总 成本为87072美元/天……统计包括网页、App和API在内的所有负载，如果所有tokens全部按照DeepSeek-R1的定价计算，理论上一天的总收入为562027美元，成本 利润率为545%。 文章一经发出，不少网友纷纷在评论区@尤洋。尤洋是潞晨科技创始人。此前，尤洋公开表示，卖DeepSeek API（MaaS）每月亏本4亿元。该消息一度引起轰 动。目前，尤洋已回应称，"由于多人at我，我今天（3月1日）之内会直接地回复一下"。 理论上一天的成本利润率为545% 文章中，DeepSeek首次披露成本利润率关键信息。DeepSeek统计了在24小时统计时段内DeepSeek-V3和R1网页、App和API的所有负载，所有tokens按照DeepSeek- R1的定价，并假定GPU租赁成本为2美元/小时，总成本为87072美元一天。DeepSeek称理论上一天的成本利润率为545%。 其中，DeepSeek称，在最近的24小时里（北京时间2025 ...

Douglas Dynamics (PLOW) Q4 2024 Earnings Call February 25, 2025 10:00 AM ET Company Participants Nathan Elwell - VP - Investor RelationsJames Janik - ChairmanMark Van Genderen - President & CEOSarah Lauber - Executive VP, CFO & Secretary Conference Call Participants Michael Shlisky - Managing Director & Senior Equity Research AnalystGregory Burns - Analyst Operator Good day, and welcome to the Douglas Dynamics Fourth Quarter twenty twenty four Earnings Conference Call. All participants will be in a listen o ...

Financial Data and Key Metrics Changes - The company generated total adjusted revenues of $730 million in Q4 2024, resulting in 6% organic growth, which was above expectations [18] - For the full year, total adjusted revenue was $2.76 billion, with 1% organic growth [19] - Adjusted EPS for Q4 was $1.42, exceeding guidance by $0.04, and for the full year, adjusted EPS was $4.90, representing 5% growth year over year [21][22] Business Line Data and Key Metrics Changes - Life Sciences segment generated $336 million in Q4, up 5% on both a reported and organic basis, but down low single digits for the full year [25] - Diagnostics segment generated $393 million in Q4, up 4% on a reported basis and 6% on an organic basis, with 4% organic growth for the full year [27] - The Life Sciences instruments revenue was down high single digits in Q4 and down low double digits for the full year [25] Market Data and Key Metrics Changes - In Q4, organic revenue growth was 5% in Life Sciences and 6% in Diagnostics, with mid single digits growth in the Americas, low single digits in Europe, and mid single digits in Asia, particularly high single digits in China [23] - For the full year, China experienced low single digit growth in diagnostics and mid teens growth in life sciences, but overall, China declined in the low single digits organically [24] Company Strategy and Development Direction - The company plans to step up strategic internal investments in 2025, expecting organic growth to improve [9][31] - A new Life Sciences Solutions business unit will be established, representing approximately 85% of the Life Sciences segment, reflecting a re-segmentation of the Applied Genomics business [14] - The company aims for adjusted operating margin expansion of 20 to 40 basis points in 2025, despite increased investments [31] Management's Comments on Operating Environment and Future Outlook - Management noted that while demand trends have stabilized, the pace of recovery remains uncertain, leading to a cautious outlook for 2025 [39] - The company expects total organic growth in 2025 to be in the range of 3% to 5%, with balanced growth expected throughout the year [30] - Management expressed optimism about the potential for recovery in the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Other Important Information - The company repurchased $185 million worth of shares in Q4, bringing total buyback activity for 2024 to $370 million [22] - Free cash flow for Q4 was $151 million, with a full year total of $578 million, equating to 96% conversion of adjusted net income [22] Q&A Session Summary Question: Insights on key end markets and recovery areas - Management acknowledged a path to recovery but emphasized uncertainty in the pace of return to normalcy, with diagnostics and software businesses showing signs of improvement while instrumentation remains a concern [39][40] Question: Guidance for China and stimulus impact - Management expects China to align with company growth averages, with modest stimulus impact anticipated [41][42] Question: Segment outlooks relative to overall guidance - Diagnostics is expected to perform above the company average, while Life Sciences is projected to be in the low single digits [46][47] Question: Expectations for reagents growth - Management indicated that the reagents business is gaining market share and is expected to grow in mid single digits for fiscal 2025 [48][50] Question: Q1 guidance and margin visibility - Management noted that Q1 margins are typically below the full year average, with a similar cadence expected as in 2024 [54] Question: Applied Genomics recovery expectations - Management expressed optimism about the recovery of the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Question: FX impact on margins - Management clarified that FX does not have a material impact on operating margins [66] Question: Strategic investments for 2025 - Management highlighted increased investments in digital capabilities and expanding sales channels as part of their strategy for 2025 [70]

Dover (DOV) Q4 2024 Earnings Call January 30, 2025 04:16 PM ET Company Participants Jack Dickens - Senior Director of Investor RelationsRichard Tobin - President, CEO & Chairman of the BoardBrad Cerepak - Senior VP & CFOSteve Tusa - Managing DirectorNigel Coe - Managing DirectorJoe Ritchie - Managing DirectorBrett Linzey - Executive DirectorMichael Halloran - Associate Director of ResearchJeffrey Sprague - Managing PartnerAndrew Obin - MD - Equity ResearchScott Davis - CEO & ChairmanDeane Dray - Managing Di ...